Total submissions: 5
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Labcorp Genetics |
RCV000554329 | SCV000644687 | benign | Tuberous sclerosis 2 | 2025-02-02 | criteria provided, single submitter | clinical testing | |
Gene |
RCV001566191 | SCV001789673 | likely benign | not provided | 2021-03-30 | criteria provided, single submitter | clinical testing | |
Genome- |
RCV000554329 | SCV002041285 | benign | Tuberous sclerosis 2 | 2021-11-07 | criteria provided, single submitter | clinical testing | |
All of Us Research Program, |
RCV003999345 | SCV004828961 | uncertain significance | Tuberous sclerosis syndrome | 2023-06-08 | criteria provided, single submitter | clinical testing | This variant causes a C to T nucleotide substitution at the -10 position of intron 10 of the TSC2 gene. Splice site prediction tools suggest that this variant may impact RNA splicing. To our knowledge, functional studies have not been reported for this variant. This variant has not been reported in individuals affected with tuberous sclerosis complex in the literature. This variant has been identified in 6/251232 chromosomes in the general population by the Genome Aggregation Database (gnomAD). The available evidence is insufficient to determine the role of this variant in disease conclusively. Therefore, this variant is classified as a Variant of Uncertain Significance. |
Myriad Genetics, |
RCV000554329 | SCV005406047 | benign | Tuberous sclerosis 2 | 2024-09-05 | criteria provided, single submitter | clinical testing | This variant is considered benign. This variant is intronic and is not expected to impact mRNA splicing. This variant has been observed at a population frequency that is significantly greater than expected given the associated disease prevalence and penetrance. |